All In Biotech

Drug Trial Radar · NCT07093008

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

A Phase 1, Investigator- and Participant-blinded, Placebo-Controlled, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Formulations of AQ280 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

9

Actual

Start

Jun 13, 2025

Primary completion

Jul 16, 2025

Study completion Jul 22, 2025

Sponsor

Lead sponsor
AQILION ABIndustry
Sponsor type
Industry
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • AQ280 CapsuleDrug

    AQ280 administered orally in capsule formulation.

  • AQ280 Tablet for Oral SuspensionDrug

    AQ280 administered orally in tablet for oral suspension formulation.

  • Placebo CapsuleDrug

    Placebo administered orally in capsule formulation.

  • Placebo Tablet for Oral SuspensionDrug

    Placebo administered orally in tablet for oral suspension formulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of AUC0-Inf for AQ280 Capsule vs Oral SuspensionTime frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  2. Ratio of Cmax for AQ280 Capsule vs Oral SuspensionTime frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  3. Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  4. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  5. Maximum Observed Concentration (Cmax)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  6. Time of the Maximum Observed Concentration (Tmax)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  7. Apparent Terminal Elimination Half-life (t1/2)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  8. Apparent Total Clearance (CL/F)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)
  9. Apparent Volume of Distribution During the Terminal Phase (Vz/F)Time frame: Pre dose and up to 48 hours post dose (up to end of study - approximately 7 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.